Amarin Corp Plc (AMRN)

[ziploc_1]

Tal...I have been thinking along the same lines...

QUOTE..."Vascepa has no market value on its own. Its sole value resides rather in a reformulation of the molecule so that what gets sold is a new improved “Statin+” rather than Vascepa, thereby short-cutting the entire lengthy marketing regulatory approval / reimbursement / budget allocation / sales processes worldwide – processes that can be hindered by a variety of geopolitical, financial, economic, generic competition and bureaucratic factors.
Only a BP selling a statin can integrate this molecule into its product and ESTABLISHED market."

Thus far, Amarin has not taken advantage of its EXCLUSIVE CONTRACT with Mochida to 'collaborate' on new and improved molecules of EPA which Amarin can market in 'certain territories'...

Amarin paid Mochida $2 million up front at the signing of their agreement to 'collaborate' on new EPA products...It seems that this is the moment to bring this critical agreement out of Amarin's back room, dust it off, and put it to work.